PRQR · ProQR Therapeutics N.V. Ordinary Shares
View on chartInsiders & Stakes
| de Boer Daniel Anton Chief Executive Officer | ▲ Buy | Open Market | 500,000 Shares held | 7/31/2026 | View profile |
| Bart Filius Director | ▲ Buy | Open Market | 300,000 Shares held | 7/17/2026 | View profile |
Transaction History
| de Boer Daniel Anton | ▲ Buy | Open Market | 200,000 | $354K | 7/31/2026 |
| Bart Filius | ▲ Buy | Open Market | 150,000 | $258K | 7/17/2026 |
| de Boer Daniel Anton | ▲ Buy | Open Market | 150,000 | $261K | 7/9/2026 |
| de Boer Daniel Anton | ▲ Buy | Open Market | 150,000 | $239K | 7/7/2026 |
| Bart Filius | ▲ Buy | Open Market | 150,000 | $231K | 6/26/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ProQR Appoints New Chief Data and AI Officer and Board Advisor
ProQR Therapeutics has named Chris Hart as its new Chief Data and AI Officer and added Thomas Wolf to the board as a Strategic AI Advisor. These appointments signal a strategic focus on integrating artificial intelligence into the company's operations. The stock is currently trading near its 52-week low, with the recent leadership changes occurring while the share price remains well below the average analyst target.
ProQR Appoints New Chief Data and AI Officer and Board Advisor. ProQR Therapeutics has named Chris Hart as its new Chief Data and AI Officer and added Thomas Wolf to the board as a Strategic AI Advisor. These appointments signal a strategic focus on integrating artificial intelligence into the company's operations. The stock is currently trading near its 52-week low, with the recent leadership changes occurring while the share price remains well below the average analyst target.